Back to Search
Start Over
Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection.
- Source :
- PLoS ONE; 6/9/2016, Vol. 11 Issue 6, p1-17, 17p
- Publication Year :
- 2016
-
Abstract
- The ultimate goal of pegylated interferon-alfa-2a (Peg-IFN-α) therapy in chronic hepatitis B (CHB) infection is HBsAg seroconversion. Even though B cells are major mediators of a positive clinical outcome, their modulation during Peg-IFN-α therapy has not yet been described. We investigated here the effects of Peg-IFN-α on eight circulating B-cell subsets thanks to an original multi-gating approach based on CD19, CD27, IgD, CD10, and CD38 markers in patients with CHB treated with nucleos(t)ide analog alone or in combination with Peg-IFN-α. These dynamic changes were analyzed during the 48-weeks of Peg-IFN-α therapy and up to 2 years after the cessation of treatment. The CD19<superscript>+</superscript>CD27<superscript>-</superscript>IgD<superscript>+</superscript>CD10<superscript>+</superscript>CD38<superscript>high</superscript> transitional B cells and the CD19<superscript>+</superscript>CD27<superscript>+</superscript>IgD<superscript>-</superscript>CD10<superscript>-</superscript>CD38<superscript>high</superscript> plasmablasts continuously increased, whereas the CD19<superscript>+</superscript>CD27<superscript>-</superscript>IgD<superscript>+</superscript>CD10<superscript>-</superscript>CD38<superscript>low</superscript> naive, CD19<superscript>+</superscript>CD27<superscript>+</superscript>IgD<superscript>+</superscript> natural memory, and CD19<superscript>+</superscript>CD27<superscript>+</superscript>IgD<superscript>-</superscript>CD10<superscript>-</superscript>CD38<superscript>low</superscript> post-germinal center B cells decreased during the course of Peg-IFNα treatment. Such modulations correlated with a sustained increase in sCD30 levels and the decrease in plasma HBsAg. However, no seroconversion occurred and all parameters returned to baseline after the stop of the treatment. Peg-IFN-α therapy mediates a remodeling of B-cell compartmentalization, without clinical relevance. Our study provides new insights into the immunomodulatory effects of Peg-IFN-α on circulating B-cells, and questioned the benefit of the add-on Peg-IFN-α treatment in CHB. [ABSTRACT FROM AUTHOR]
- Subjects :
- B cells
INTERFERON genetics
CHRONIC hepatitis B
SEROCONVERSION
PATIENTS
THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 19326203
- Volume :
- 11
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- PLoS ONE
- Publication Type :
- Academic Journal
- Accession number :
- 116024670
- Full Text :
- https://doi.org/10.1371/journal.pone.0156200